Experts warn against untrained cosmetic procedures at SafePlast-2025 meet
Renowned Dubai-based plastic surgeon Dr. Sanjay Parashar cautioned that even with full effort, aesthetic surgeries carry risks. 'Complications can occur despite precision. Proper training, not just book knowledge, is essential. Treatments like liposuction, facial corrections, and hair transplants require extreme care,' he said, stressing infection prevention and patient satisfaction as top priorities.
Dr. Gurukarna Vemula, Managing Director of Personix Cosmetics & Plastic Surgery Centre, urged patients to verify doctors' credentials before treatment. 'Check for recognised degrees like MBBS, MD, MCh and state medical council registration. Avoid untrained practitioners, as botched hair transplants, Botox, and laser treatments can lead to infections and other side effects,' he warned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
an hour ago
- Hans India
Ailing Tripura Assembly Speaker in Bengaluru for treatment
Agartala: Tripura Assembly Speaker Biswa Bandhu Sen, who underwent an emergency surgical procedure at a private hospital here after he suffered a massive cerebral stroke on August 8, was taken to a Bengaluru facility for better treatment on Monday, his family said. Two doctors from AIIMS, New Delhi, came here on Sunday to provide an expert opinion on the condition of Sen who is 72 years old. 'They (doctors from AIIMS) thoroughly examined the patient and reviewed his case with a team of treating doctors. The experts confirmed that the initial management and timely brain decompression surgery had been appropriate,' the private ILS hospital here said in a Arijit Sen, the son of the Speaker, told reporters that his father's condition is stable with all vital organs functioning normally after the brain surgery.'We shifted him to a Bangalore-based hospital for further treatment,' he said. He thanked Chief Minister Manik Saha for properly managing the initial treatment of his Speaker suffered a brain haemorrhage at Agartala railway station on August referring to the opposition CPI(M)'s criticism of the Speaker's treatment in a private medicare facility here instead of GBP Hospital, a tertiary care institution for Heart, Brain and other disorders, his son said it was the family's decision to treat him there. 'He is our father, and we will decide where he will be treated. Nobody could dictate that to us. It is not good to play politics over an ailing person,' he said.
Time of India
an hour ago
- Time of India
Explosion at US Steel plant in Pennsylvania leaves 2 dead, 10 injured
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel An explosion at a US Steel plant near Pittsburgh left two dead and sent at least 10 to hospitals Monday and heavily damaged the sprawling facility, officials worker was pulled from the wreckage hours after the explosion sent black smoke spiraling into the midday sky in the Mon Valley, a region of the state synonymous with steel for more than a century. Allegheny County Emergency Services said a fire at the plant started around 10.51 am. Authorities later said a second person had explosion, followed by several smaller blasts, could be felt in the nearby community and prompted county officials to warn residents to stay away from the scene so emergency workers could respond."It felt like thunder," Zachary Buday, a construction worker near the scene, told WTAE-TV. "Shook the scaffold, shook my chest, and shook the building, and then when we saw the dark smoke coming up from the steel mill and put two and two together, and it's like something bad happened."At a news conference, Scott Buckiso, U.S. Steel's chief manufacturing officer, did not give details about the damage or casualties, and said they were still trying to determine what happened. U.S. Steel employees "did a great job" of going in and rescuing workers, shutting down gases and making sure the site was said the company, now a subsidiary of Japan-based Nippon Steel Corp., is working with authoritiesUS Steel CEO David B. Burritt said the company would thoroughly investigate the cause."I end every meeting and every message with the words, Let's get back to work safely.' That commitment has never been more important, and we will honour it," he said in a Health Network said it treated seven patients from the plant, and discharged five within a few hours. University of Pittsburgh Medical Center said it is treating three patients at UPMC Mercy, the region's only level one trauma and burn resident Amy Sowers was sitting on her porch, located less than a mile from the plant, and felt her house shake from the blast."I could see smoke from my driveway," she said. "We heard ambulances and fire trucks from every direction."Sowers, 49, decided to leave the area after she said she smelled a faint smell in the air. Sowers, who grew up in Clairton, has seen several incidents at the plant over the years. Despite health concerns, Sowers said many residents cannot afford to leave.A maintenance worker was killed in an explosion at the plant in September 2009. In July 2010, another explosion injured 14 employees and six contractors. According to online OSHA records of workplace fatalities, the last death at the plant was in 2014, when a worker was burned and died after falling into a the 2010 explosion, the Occupational Safety and Health Administration fined US Steel and a subcontractor USD 175,000 for safety violations. US Steel appealed its citations and USD 143,500 in fines, which were later reduced under a settlement agreement."Lives were lost again," Sowers said. "How many more lives are going to have to be lost until something happens?"The Clairton coking plant continued to operate after the explosion, although two batteries that were the site of the explosion were shut down, officials plant, a massive industrial facility along the Monongahela River south of Pittsburgh, is considered the largest coking operation in North America and is one of four major US Steel plants in plant converts coal to coke, a key component in the steel-making process. To make coke, coal is baked in special ovens for hours at high temperatures to remove impurities that could otherwise weaken steel. The process creates what's known as coke gas - made up of a lethal mix of methane, carbon dioxide and carbon Mayor Richard Lattanzi said his heart goes out to the victims of Monday's explosion."The mill is such a big part of Clairton," he said. "It's just a sad day for Clairton."The Allegheny County Health Department said it lifted an advisory it issued earlier in the day telling residents within 2 km of the plant to remain indoors and close all windows and doors. It said its monitors have not detected levels of soot or sulfur dioxide above federal to the company, the plant has approximately 1,400 recent years, the Clairton plant has been dogged by concerns about 2019, it agreed to settle an air pollution lawsuit for USD 8.5 million. Five years later, the company agreed to spend USD 19.5 million in equipment upgrades and USD 5 million on local clean air efforts and programs as part of settling a federal lawsuit filed by Clean Air Council and PennEnvironment and the Allegheny County Health Department. (AP)
News18
an hour ago
- News18
Hyderabad Pharma Firm To Make Drug For Hard-To-Treat Bladder Cancer After Local Trials Waiver
For Indian patients battling aggressive bladder cancer driven by specific gene changes, a vital treatment may soon be available. Citing an 'unmet medical need" India's top drug advisory panel has approved a pharmaceutical firm's request to make and sell erdafitinib tablets in India by skipping a local third-phase trial but needing a post-launch fourth phase study. Hyderabad-based Natco Pharma has presented the proposal for the grant of permission to manufacture and market erdafitinib in three different strengths along with the 'justification" for a waiver on local third-phase clinical trials, as per the minutes of the meeting of the technical committee dated July 17. 'After detailed deliberation, the committee opined that there is an unmet medical need for the proposed indication in the country," said the minutes, which were accessed by News18. 'The committee recommended for the grant of permission to manufacture and market the drug Erdafitinib Tablet 3 mg, 4 mg and 5 mg with local Phase III clinical trial waiver." This marks a significant shift from the 2023 stance, when the subject expert committee (SEC), functioning under Central Drugs Standard Control Organisation (CDSCO), had rejected Natco's request for a Phase-III waiver. After reviewing the bioequivalence data, the SEC asked the company to 'submit the Phase-III clinical trial protocol before the committee for further consideration". That earlier decision underscored the caution about approving cancer treatments without robust local safety and efficacy data. According to the GLOBOCAN 2020 database, bladder cancer is the 17th most common malignancy in India. The five-year prevalence appears to be 3.57 per 1,00,000 population, leading to about 11,000 deaths each year. The incidence of bladder cancer is higher in males as compared to females. Data shows that bladder cancer incidence does vary across India. Among males, Delhi had the highest incidence rates followed by Thiruvananthapuram and Kolkata, and the lowest rate was in Dibrugarh. When it comes to females, the rate is highest in Delhi followed by Mumbai and Mizoram, respectively, and lowest in Barshi. Over time, bladder cancer incidence has increased in Delhi, Bengaluru and Mumbai, while it has decreased in Chennai. WHAT MAKES ERDAFITINIB IMPORTANT? Erdafitinib is a targeted therapy that inhibits the fibroblast growth factor receptor (FGFR) – a key driver of rapid tumour growth in certain bladder cancers. The FGFR gene gives the body instructions to make FGFR proteins, which sit on the surface of cells. These proteins receive growth signals (called fibroblast growth factors) and tell the cell when to grow, divide, or repair itself. On January 19, 2024, the US FDA approved erdafitinib, sold under the brand name Balversa, developed by Janssen Biotech, a Johnson & Johnson company. The drug has been approved for adults with advanced or metastatic bladder cancer that has certain FGFR3 gene changes, confirmed by an approved test. It can be used if the cancer has worsened after at least one previous systemic treatment. It is not meant for patients who could still benefit from PD-1 or PD-L1 immunotherapy and have not yet tried it. ONCOLOGISTS WELCOME THE MOVE According to the sellers on the online platform Indiamart, the bottle containing 56 tablets of 4mg Erdafitinib is sold at Rs 7,000, which is Rs 125 per tablet. With local manufacturing, however, the cost is expected to drop by more than 50 per cent. 'It's a good drug for bladder cancer patients with locally advanced disease not responding to chemotherapy. This is targeted therapy that blocks fibroblast growth factor receptor (FGFR). This fibroblast growth factor helps cancer grow fast. This medicine blocks this growth and helps control cancer," said Dr Satya Prakash Yadav, director of paediatric haematology-oncology and bone marrow transplant at Medanta Hospital. Similarly, Dr Pragya Shukla, who leads the clinical oncology department at Delhi State Cancer Institute, said the drug is for FGFR-altered metastatic urothelium, which has failed on multiple lines of chemotherapy and has shown benefits in overall survival in this particular group of patients. As the panel cited 'unmet demand", Dr Shukla said: 'The drug should definitely benefit a particular group of patients waiting for a targeted therapy." WHAT COMES NEXT? If the technical committee's recommendation is adopted into a final CDSCO order, Natco Pharma may roll out erdafitinib across India – provided it submits a robust Phase-IV study protocol within three months of approval. A fourth phase trial is the stage of research that happens after a drug has been approved by regulators and is already being sold in the market. It is also called post-marketing surveillance or post-approval study. It can reveal safety issues, interactions, or benefits that did not appear in smaller or shorter trials before, and at times lead to changes in how the drug is prescribed – or even withdrawal if serious risks are found.
